BioCentury
ARTICLE | Clinical News

InflammaGen Shok-Pak: Phase II started

March 26, 2012 7:00 AM UTC

InflammaGen Therapeutics Inc., part of Leading BioSciences, began a double-blind, U.S. Phase II trial to compare InflammaGen Shok-Pak vs. standard therapy in about 200 critically-ill ICU patients. ...